Benutzer: Gast  Login
Weniger Felder
Einfache Suche
Titel:

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Dokumenttyp:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Article
Autor(en):
Walter, M; Philotheou, A; Bonnici, F; Ziegler, AG; Jimenez, R
Abstract:
OBJECTIVE: This randomized, four-arm, placebo-controlled, dose-ranging phase 2 trial was conducted to determine whether repeated subcutaneous injections of the altered peptide ligand, NBI-6024, designed to inhibit autoreactive T-cells, improves beta-cell function in patients with recently diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS: A total of 188 patients, aged 10-35 years, with recently diagnosed type 1 diabetes were randomly assigned for a treatment consisting of the subcutaneous a...     »
Zeitschriftentitel:
Diabetes Care
Jahr:
2009
Band / Volume:
32
Heft / Issue:
11
Seitenangaben Beitrag:
2036-40
Sprache:
eng
Volltext / DOI:
doi:10.2337/dc09-0449
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/19690081
Print-ISSN:
0149-5992
TUM Einrichtung:
Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin
 BibTeX